Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor.
GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial.
Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.
Company Details
- Employees
- 12
- Founded
- 2019
- Address
- 1077 Zhangheng Road, Atlatl Innovation Research And Development Center,china
- Industry
- Biotechnology
- Website
- https://www.grit-bio.com/
- Keywords
- TIL, TIL Therapy, Cell Therapy.
- HQ
- Pudong New Area, Shanghai, Shanghai
Grit Biotechnology Questions
Grit Biotechnology's website is https://www.grit-bio.com/
Grit Biotechnology's LinkedIn profile is https://cn.linkedin.com/company/grit-biotechnology
Grit Biotechnology has
12 employees.
View email and phone details for 12
employees at Grit Biotechnology.
Grit Biotechnology's industry is
Biotechnology
Grit Biotechnology's top competitors are
Carsgen Therapeutics,
Star Therapeutics,
Stylus Medicine,
Grit Bio, Inc.,
Huidagene Therapeutics,
Inceptor Bio,
Hyku Biosciences,
Juncell Therapeutics,
Cabaletta Bio,
Precision Biosciences, Inc..
Grit Biotechnology's categories are Biotechnology
Grit Biotechnology's founding year is 2019
